Is This the Secret Ingredient That Could Make Moderna Shareholders Rich?
With the advances in both software and hardware, investors are recognizing that every company is a technology company. Rather than a back office function supporting a few productivity tools, technology has become a differentiator in industries that may seem to have little to do with software and semiconductors.
In the biotech industry, Moderna (NASDAQ: MRNA) recognized this from the start. It was founded in 2010 with an eye on tech-enabled speed as its killer app. The company leveraged the foresight during the pandemic to deliver a COVID vaccine in less than a year. Looking toward the future, management continues to highlight how technology will be the driving force behind its success as a new kind of drug developer.
Image source: Getty Images.
Source Fool.com
